Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice. / Clemmensen, Christoffer; Finan, Brian; Fischer, Katrin; Tom, Robby Zachariah; Legutko, Beata; Sehrer, Laura; Heine, Daniela; Grassl, Niklas; Meyer, Carola W; Henderson, Bart; Hofmann, Susanna M; Tschöp, Matthias H; Van der Ploeg, Lex H T; Müller, Timo D.
In: EMBO Molecular Medicine, Vol. 7, No. 3, 03.2015, p. 288-98.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice
AU - Clemmensen, Christoffer
AU - Finan, Brian
AU - Fischer, Katrin
AU - Tom, Robby Zachariah
AU - Legutko, Beata
AU - Sehrer, Laura
AU - Heine, Daniela
AU - Grassl, Niklas
AU - Meyer, Carola W
AU - Henderson, Bart
AU - Hofmann, Susanna M
AU - Tschöp, Matthias H
AU - Van der Ploeg, Lex H T
AU - Müller, Timo D
N1 - © 2015 The Authors. Published under the terms of the CC BY 4.0 license.
PY - 2015/3
Y1 - 2015/3
N2 - We assessed the efficacy of simultaneous agonism at the glucagon-like peptide-1 receptor (GLP-1R) and the melanocortin-4 receptor (MC4R) for the treatment of obesity and diabetes in rodents. Diet-induced obese (DIO) mice were chronically treated with either the long-acting GLP-1R agonist liraglutide, the MC4R agonist RM-493 or a combination of RM-493 and liraglutide. Co-treatment of DIO mice with RM-493 and liraglutide improves body weight loss and enhances glycemic control and cholesterol metabolism beyond what can be achieved with either mono-therapy. The superior metabolic efficacy of this combination therapy is attributed to the anorectic and glycemic actions of both drugs, along with the ability of RM-493 to increase energy expenditure. Interestingly, compared to mice treated with liraglutide alone, hypothalamic Glp-1r expression was higher in mice treated with the combination therapy after both acute and chronic treatment. Further, RM-493 enhanced hypothalamic Mc4r expression. Hence, co-dosing with MC4R and GLP-1R agonists increases expression of each receptor, indicative of minimized receptor desensitization. Together, these findings suggest potential opportunities for employing combination treatments that comprise parallel MC4R and GLP-1R agonism for the treatment of obesity and diabetes.
AB - We assessed the efficacy of simultaneous agonism at the glucagon-like peptide-1 receptor (GLP-1R) and the melanocortin-4 receptor (MC4R) for the treatment of obesity and diabetes in rodents. Diet-induced obese (DIO) mice were chronically treated with either the long-acting GLP-1R agonist liraglutide, the MC4R agonist RM-493 or a combination of RM-493 and liraglutide. Co-treatment of DIO mice with RM-493 and liraglutide improves body weight loss and enhances glycemic control and cholesterol metabolism beyond what can be achieved with either mono-therapy. The superior metabolic efficacy of this combination therapy is attributed to the anorectic and glycemic actions of both drugs, along with the ability of RM-493 to increase energy expenditure. Interestingly, compared to mice treated with liraglutide alone, hypothalamic Glp-1r expression was higher in mice treated with the combination therapy after both acute and chronic treatment. Further, RM-493 enhanced hypothalamic Mc4r expression. Hence, co-dosing with MC4R and GLP-1R agonists increases expression of each receptor, indicative of minimized receptor desensitization. Together, these findings suggest potential opportunities for employing combination treatments that comprise parallel MC4R and GLP-1R agonism for the treatment of obesity and diabetes.
KW - Animals
KW - Diabetes Mellitus
KW - Drug Synergism
KW - Drug Therapy, Combination
KW - Glucagon-Like Peptide 1
KW - Glucagon-Like Peptide-1 Receptor
KW - Hypoglycemic Agents
KW - Liraglutide
KW - Mice, Obese
KW - Obesity
KW - Receptor, Melanocortin, Type 4
KW - Receptors, Glucagon
KW - Treatment Outcome
KW - alpha-MSH
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
U2 - 10.15252/emmm.201404508
DO - 10.15252/emmm.201404508
M3 - Journal article
C2 - 25652173
VL - 7
SP - 288
EP - 298
JO - EMBO Molecular Medicine
JF - EMBO Molecular Medicine
SN - 1757-4676
IS - 3
ER -
ID: 186640302